 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ: XNCR, a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on two novel XmAb cytokine programs at the American Association for Cancer Research AACR Annual Meeting, being held April 8-13, 2022 at the New Orleans Ernest N. Morial Convention Center in New Orleans. Cytokines evolved to be highly activ 